On Thursday, Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) announced the outcome of the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee Meeting to review the company’s New Drug Application (NDA) for Zynquista (sotagliflozin). The company is seeking approval for the oral SGLT1/SGLT2 inhibitor as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes (T1D) and chronic kidney disease (CKD). The Advisory Committee voted 11 to 3 that the benefits of Zynquista do not outweigh the risks, as having an estimated glomerular filtration rate (eGFR) >45 to <60 mL/min.1.7...